Page 1 of 1
New study posted on clinical trials site
Posted: Thu May 12, 2022 4:02 pm
by biopearl123
Re: New study posted on clinical trials site
Posted: Fri May 13, 2022 4:52 am
by LWS
Incyte is interested in an Imetelstat combination
-------------------------
How does ruxolitinib work in myelofibrosis?
Ruxolitinib is a janus kinase inhibitor ( JAK inhibitor) with selectivity for subtypes JAK1 and JAK2. Ruxolitinib inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression
Is opzelura cream the same as ruxolitinib?
"Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura. Opzelura is a trademark of Incyte. OPZELURA cream is for use on the skin only. Do not use OPZELURA cream in your eyes, mouth or vagina. Serious Infections: OPZELURA cream contains ruxolitinib."
What type of cancer is Ruxolitinib used to treat?
Ruxolitinib (Jakavi ®) is used to treat some types of myeloproliferative neoplasms (MPNs). MPNs are types of cancer that affect how blood cells are made.
--------------------------------------------
Ruxolitinib
Common brand names: Jakafi
This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera).
May Treat: Polycythemia vera · Graft versus host disease · Myelofibrosis · Thrombocytosis in myeloproliferative disease
Brand Names: Jakafi
Drug Class: Antineoplastic - Janus Kinase (JAK) Inhibitors
Availability: Prescription Required
Pregnancy: Consult a doctor before using
Lactation: This drug should not be given to breastfeeding mothers
Driving: May cause drowsiness or dizziness. Use caution
Precautions
If available, read the patient package insert
Call MD for fever, chills or persistent sore throat
Tell MD immediately of easy bruising or bleeding
May make you dizzy. Use caution when driving.
Avoid taking grapefruit juice/grapefruit with med
MD may need to reduce the dose before you stop it.
Not recommended when breast feeding
Lab tests may be ordered to monitor therapy